Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Cenerimod · ACT-334441

Small molecule · developed by Viatris Innovation GmbH

Phase 3 Most advanced trial
VTRS Developer
5 Registered trials

What is Cenerimod?

Cenerimod (ACT-334441) is an oral drug studied in systemic lupus erythematosus, including lupus nephritis, and in healthy subjects.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ACT-334441
Drug type
Small molecule
Therapy area
Immunology, Renal & urology
Developer
Viatris Innovation GmbH (VTRS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
Y333RS1786

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07201129 Phase 3 Nephritis, Lupus Recruiting VTRS
NCT07266090 Phase 2 SLE - Systemic Lupus Erythematosus Active not recruiting VTRS
NCT03742037 Phase 2 Systemic Lupus Erythematosus Completed VTRS
NCT07301723 Phase 1 Healthy Subjects Completed VTRS
NCT02479204 Phase 1 Healthy Subjects Terminated VTRS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Lupus Erythematosus, SystemicNephritis, LupusSLE - Systemic Lupus ErythematosusHealthy SubjectsSystemic Lupus Erythematosus

More from Viatris Innovation GmbH

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the VTRS page.

Follow VTRS, the company behind Cenerimod

See VTRS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VTRS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.